Alnylam Pharmaceuticals Inc logo

ALNY

Alnylam Pharmaceuticals Inc

$222.09

Earnings Summary

Revenue
$224.82Mn
Net Profits
$-277.4Mn
Net Profit Margins
-123.39%

Highlights

Revenue:

Alnylam Pharmaceuticals Inc’s revenue jumped 1.93% since last year same period to $224.82Mn in the Q2 2022. On a quarterly growth basis, Alnylam Pharmaceuticals Inc has generated 5.42% jump in its revenue since last 3-months.

Net Profits:

Alnylam Pharmaceuticals Inc’s net profit fell -46.34% since last year same period to $-277.4Mn in the Q2 2022. On a quarterly growth basis, Alnylam Pharmaceuticals Inc has generated -15.42% fall in its net profits since last 3-months.

Net Profit Margins:

Alnylam Pharmaceuticals Inc’s net profit margin fell -43.56% since last year same period to -123.39% in the Q2 2022. On a quarterly growth basis, Alnylam Pharmaceuticals Inc has generated -9.49% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Alnylam Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.82
EPS Estimate Current Year
-1.82

Highlights

EPS Estimate Current Quarter:

Alnylam Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -1.82 - a -11.66% fall from last quarter’s estimates.

EPS Estimate Current Year:

Alnylam Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -1.82.

Key Ratios

Key ratios of the Alnylam Pharmaceuticals Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-2.29
Return on Assets (ROA)
-0.13
Return on Equity (ROE)
-1.91
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Alnylam Pharmaceuticals Inc’s earning per share (EPS) fell -42.24% since last year same period to -2.29 in the Q2 2022. This indicates that the Alnylam Pharmaceuticals Inc has generated -42.24% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Alnylam Pharmaceuticals Inc’s return on assets (ROA) stands at -0.13.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Alnylam Pharmaceuticals Inc’s return on equity (ROE) stands at -1.91.

Dividend Per Share (DPS):

Alnylam Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-07-28
-1.63
-2.29
-40.49%
2022-04-28
-1.84
-2
-8.7%

Company Information

Alnylam Pharmaceuticals Inc. is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam's partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its 'Alnylam P5x25' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.

Organisation
Alnylam Pharmaceuticals Inc
Headquarters
Cambridge, Massachusetts, US
Employees
1.45K
Industry
Health Technology
CEO
John Maraganore